Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage
Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage
复制标题
DOI：
10.1002/cncr.21958
复制
发表时间：
2006-07-01
期刊：
影响因子：
6.2
通讯作者：
Kalaycio, M
中科院分区：
文献类型：
--
作者：
Kalmadi, S;Tiu, R;Kalaycio, M
背景。 ε-氨基己酸 (EACA) 是一种抗纤维蛋白溶解药物，可通过稳定血栓来控制出血。它已主要根据经验用于血小板减少症患者。方法。对副作用的担忧限制了这种药物的使用。作者回顾了 1997 年至 2003 年克利夫兰诊所基金会使用 EACA 的经验。结果。 77 例血小板减少性出血患者中，51 例（66%）患者获得完全缓解，13 例（17%）患者获得部分缓解，导致血小板和红细胞输注量减少。这组患有严重基础疾病的患者的不良反应是可以控制的。结论。根据这一经验，EACA可能是治疗血小板减少性出血患者的一种有价值的辅助疗法。
BACKGROUND. Epsilon aminocaproic acid (EACA) is an antifibrinolytic drug that has been used to control hemorrhage by stabilizing the thrombus. It has been used in thrombocytopenic patients largely on an empiric basis.METHODS. Concerns regarding side effects have limited the use of this drug. The authors reviewed their experience with EACA at the Cleveland Clinic Foundation from 1997 to 2003.RESULTS. Of 77 patients with thrombocytopenic hemorrhage, 51 (66%) patients achieved a complete response and 13 (17%) patients achieved a partial response, resulting in a decrease in platelet and red blood cell transfusions. Adverse effects were manageable in this set of patients with severe underlying disease.CONCLUSIONS. Based on this experience, EACA may be a valuable adjunctive therapy in the treatment of patients with thrombocytopenic hemorrhage.